Invited Commentary
Special Issue: Treatment for Adolescents With Depression
Treatment of depression in adolescents with cognitive behavior therapy and medications: A commentary on the TADS project

https://doi.org/10.1016/S1077-7229(05)80019-7Get rights and content

This article reviews and comments on the recent Treatment for Adolescents With Depression Study (TADS) that found that cognitive behavior therapy (CBT) was less efficacious than fluoxetine alone and no more efficacious than pill placebo in the treatment of depression in adolescents. Adding CBT to fluoxetine, however, improved treatment response in terms of both the reduction of depressive symptoms and the prevention of harm-related adverse events, including suicide risk. The TADS project was impressive in many respects and generally conducted well. However, the version of CBT used in this study was a novel amalgamation of different approaches, and may have tried to do too much in an overly structured fashion, thereby possibly tying the hands of the more experienced therapists in the trial. We question, therefore, the adequacy with which CBT was implemented and the representativeness of the findings. To explore these issues, we recommend that (a) the results be broken down by therapist and site, and (b) the CBT as implemented in TADS be compared to that provided in other studies that have found greater change in adolescent depression. Finally, we also question whether it was premature to move to large multisite effectiveness trials before establishing the relative efficacy of the respective interventions.

References (31)

  • BridgeJ.A. et al.

    Adolescents with depression (letter)

    JAMA

    (2004)
  • ClarkeG. et al.

    Instructor's manual for the adolescent coping with depression course (4th ed.)

    (1990)
  • CohenD. et al.

    Pharmacological treatment of adolescent major depression

    Journal of Child and Adolescent Psychopharmacology

    (2004)
  • Committee on Safety of Medicines

    Selective serotonin reuptake inhibitor (SSRI) antidepressants: Findings of the Committee on Safety of Medicine Working Group

    (2004)
  • DeRubeisR.J. et al.

    Determinants of change in cognitive therapy for depression

    Cognitive Therapy & Research

    (1990)
  • Cited by (40)

    • Double trouble: Do symptom severity and duration interact to predicting treatment outcomes in adolescent depression?

      2020, Behaviour Research and Therapy
      Citation Excerpt :

      Data from the TADS study suggest that, in adolescent depression, combination treatment appears to be the most effective treatment. Prior (see Hollon et al., 2005) and subsequent studies (Davey et al., 2019) have been more optimistic regarding the efficacy of CBT for adolescent depression. Our findings may be taken to suggest that the poor performance of CBT in TADS may have been driven by very negative outcomes in acute but non-severe depression.

    • Estimating patient-specific treatment advantages in the ‘Treatment for Adolescents with Depression Study’

      2019, Journal of Psychiatric Research
      Citation Excerpt :

      Accordingly, it featured a relatively large sample that was quite heterogeneous, mirroring the heterogeneity of patients seen in actual clinical practice (Hollon et al., 2005; March et al., 2004; TADS Team, 2005). As such, its data was believed ripe for effect-modification analysis (TADS Team, 2003, 2005), and it was suggested that the TADS results should be broadly applicable to youths seeking treatment for depression across the USA (Hollon et al., 2005; March et al., 2004; TADS Team, 2005). The model-based random forest's ability to investigate patient heterogeneity comprehensively is clearly appropriate for such a sample.

    • Treating a broader range of depressed adolescents with combined therapy

      2018, Journal of Affective Disorders
      Citation Excerpt :

      Similarly, the existing evidence concerning the effectiveness of SSRIs in depressed adolescents is inconclusive (Bridge et al., 2007; Cheung et al., 2008; Cipriani et al., 2016; Cox et al., 2012; Emslie et al., 2004; Emslie et al., 2008; Findling et al., 2013; Hetrick et al., 2012; Le Noury et al., 2015, 2016; Masi et al., 2010; Thapar et al., 2012; Usala et al., 2008; Wagner et al., 2003; Wagner et al., 2006; Wagner et al., 2004; Whittington et al., 2004), though fluoxetine – the antidepressant used in the TADS trial – is the SSRI that has received the most consistent empirical support (Cipriani et al., 2016; Masi et al., 2010; Usala et al., 2008). The negative TADS results for cognitive-behavioral therapy were surprising, as cognitive-behavioral therapy has usually been found effective and was deemed a well-established treatment for adolescent depression (Harrington et al., 1998; Hollon et al., 2005; Klein et al., 2007; Masi et al., 2010; Reinecke et al., 1998; Weersing and Brent, 2006; Weersing et al., 2017; Weersing et al., 2009; Weisz et al., 2006). The overall picture is, thus, inconclusive for cognitive-behavioral therapy alone, an antidepressant alone, and the combination in adolescents, meaning that further research is needed for clarification.

    • Combined treatment with CBT and psychopharmacology

      2017, The Science of Cognitive Behavioral Therapy
    View all citing articles on Scopus
    View full text